BioNxt Advances Patent Filings for Novel Drug Delivery

BioNxt Solutions Inc. has announced the nationalization of patents for sublingual anticancer drugs targeting autoimmune neurodegenerative diseases. These patents, fully owned by BioNxt, have been positively reviewed by the European Patent Office under the Patent Cooperation Treaty. The company is proceeding with filings in Australia, Canada, New Zealand, the USA, and Japan, alongside various European and Eurasian nations.

This patent family is expected to offer protection until 2045. BioNxt's key project is a sublingual Cladribine product for Multiple Sclerosis (MS), offering benefits for patients with Dysphagia. Additionally, they are developing a sublingual Cladribine for Myasthenia Gravis (MG). The growing demand for innovative CNS drug delivery systems aligns with the company’s strategic focus on these markets.